vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and WEYCO GROUP INC (WEYS). Click either name above to swap in a different company.

WEYCO GROUP INC is the larger business by last-quarter revenue ($68.0M vs $45.1M, roughly 1.5× Amarin Corp plc). WEYCO GROUP INC runs the higher net margin — 9.0% vs -23.3%, a 32.3% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs -0.0%). Over the past eight quarters, WEYCO GROUP INC's revenue compounded faster (3.1% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Weyco Group is an American footwear company that designs, markets and distributes brand names including Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters and Umi. The company, which focuses on North American wholesale and retail distribution, has been assembled by a series of acquisitions.

AMRN vs WEYS — Head-to-Head

Bigger by revenue
WEYS
WEYS
1.5× larger
WEYS
$68.0M
$45.1M
AMRN
Growing faster (revenue YoY)
AMRN
AMRN
+7.0% gap
AMRN
7.0%
-0.0%
WEYS
Higher net margin
WEYS
WEYS
32.3% more per $
WEYS
9.0%
-23.3%
AMRN
Faster 2-yr revenue CAGR
WEYS
WEYS
Annualised
WEYS
3.1%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
AMRN
AMRN
WEYS
WEYS
Revenue
$45.1M
$68.0M
Net Profit
$-10.5M
$6.1M
Gross Margin
44.2%
Operating Margin
35.5%
11.0%
Net Margin
-23.3%
9.0%
Revenue YoY
7.0%
-0.0%
Net Profit YoY
33.0%
10.4%
EPS (diluted)
$0.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
WEYS
WEYS
Q1 26
$45.1M
$68.0M
Q4 25
$49.2M
$76.8M
Q3 25
$49.7M
$73.1M
Q2 25
$72.7M
$58.2M
Q1 25
$42.0M
$68.0M
Q4 24
$62.3M
$80.5M
Q3 24
$42.3M
$74.3M
Q2 24
$67.5M
$63.9M
Net Profit
AMRN
AMRN
WEYS
WEYS
Q1 26
$-10.5M
$6.1M
Q4 25
$-1.2M
$8.7M
Q3 25
$-7.7M
$6.6M
Q2 25
$-14.1M
$2.3M
Q1 25
$-15.7M
$5.5M
Q4 24
$-48.6M
$10.0M
Q3 24
$-25.1M
$8.1M
Q2 24
$1.5M
$5.6M
Gross Margin
AMRN
AMRN
WEYS
WEYS
Q1 26
44.2%
Q4 25
47.1%
44.1%
Q3 25
44.7%
40.7%
Q2 25
69.2%
43.3%
Q1 25
59.8%
44.6%
Q4 24
-15.4%
47.9%
Q3 24
38.5%
44.3%
Q2 24
63.4%
43.9%
Operating Margin
AMRN
AMRN
WEYS
WEYS
Q1 26
35.5%
11.0%
Q4 25
-12.9%
13.3%
Q3 25
-22.4%
11.0%
Q2 25
-22.0%
6.7%
Q1 25
-39.9%
10.3%
Q4 24
-84.3%
14.3%
Q3 24
-59.5%
13.7%
Q2 24
-0.8%
10.4%
Net Margin
AMRN
AMRN
WEYS
WEYS
Q1 26
-23.3%
9.0%
Q4 25
-2.5%
11.3%
Q3 25
-15.6%
9.0%
Q2 25
-19.4%
3.9%
Q1 25
-37.4%
8.1%
Q4 24
-78.0%
12.4%
Q3 24
-59.4%
10.8%
Q2 24
2.3%
8.8%
EPS (diluted)
AMRN
AMRN
WEYS
WEYS
Q1 26
$0.64
Q4 25
$0.00
$0.91
Q3 25
$-0.02
$0.69
Q2 25
$-0.03
$0.24
Q1 25
$-0.04
$0.57
Q4 24
$-0.12
$1.04
Q3 24
$-0.06
$0.84
Q2 24
$0.00
$0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
WEYS
WEYS
Cash + ST InvestmentsLiquidity on hand
$307.8M
$89.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$243.6M
Total Assets
$645.8M
$296.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
WEYS
WEYS
Q1 26
$307.8M
$89.0M
Q4 25
$302.6M
$96.0M
Q3 25
$286.6M
$72.9M
Q2 25
$298.7M
$77.4M
Q1 25
$281.8M
$71.5M
Q4 24
$294.2M
$71.0M
Q3 24
$305.7M
$75.5M
Q2 24
$306.7M
$78.4M
Stockholders' Equity
AMRN
AMRN
WEYS
WEYS
Q1 26
$243.6M
Q4 25
$459.3M
$239.6M
Q3 25
$458.9M
$251.3M
Q2 25
$464.9M
$248.1M
Q1 25
$473.7M
$248.6M
Q4 24
$486.2M
$245.6M
Q3 24
$531.4M
$258.1M
Q2 24
$551.9M
$251.2M
Total Assets
AMRN
AMRN
WEYS
WEYS
Q1 26
$645.8M
$296.3M
Q4 25
$670.8M
$319.7M
Q3 25
$659.8M
$304.0M
Q2 25
$670.1M
$300.9M
Q1 25
$655.7M
$299.3M
Q4 24
$685.3M
$324.1M
Q3 24
$750.6M
$314.7M
Q2 24
$799.9M
$303.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
WEYS
WEYS
Operating Cash FlowLast quarter
$17.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
2.85×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
WEYS
WEYS
Q1 26
$17.4M
Q4 25
$15.3M
$24.0M
Q3 25
$-12.7M
$-1.1M
Q2 25
$16.6M
$10.2M
Q1 25
$-12.5M
$4.1M
Q4 24
$-13.3M
$20.4M
Q3 24
$-2.4M
$-374.0K
Q2 24
$-2.7M
$3.3M
Free Cash Flow
AMRN
AMRN
WEYS
WEYS
Q1 26
Q4 25
$23.1M
Q3 25
$-1.3M
Q2 25
$10.0M
Q1 25
$3.7M
Q4 24
$19.9M
Q3 24
$-930.0K
Q2 24
$3.2M
FCF Margin
AMRN
AMRN
WEYS
WEYS
Q1 26
Q4 25
30.1%
Q3 25
-1.8%
Q2 25
17.1%
Q1 25
5.5%
Q4 24
24.8%
Q3 24
-1.3%
Q2 24
4.9%
Capex Intensity
AMRN
AMRN
WEYS
WEYS
Q1 26
Q4 25
1.1%
Q3 25
0.3%
Q2 25
0.4%
Q1 25
0.6%
Q4 24
0.6%
Q3 24
0.7%
Q2 24
0.3%
Cash Conversion
AMRN
AMRN
WEYS
WEYS
Q1 26
2.85×
Q4 25
2.76×
Q3 25
-0.17×
Q2 25
4.53×
Q1 25
0.74×
Q4 24
2.04×
Q3 24
-0.05×
Q2 24
-1.81×
0.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

WEYS
WEYS

Segment breakdown not available.

Related Comparisons